Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, Open-label, Non-interventional Study of Total Cholesterol/LDL-cholesterol Management in Real Life in Coronary Patients Hospitalised for Elective PCI

The purpose of the study is to follow the management of blood lipids in patients with planned percutaneous coronary intervention (widening of coronary vessels) in a period from 6 to 10 weeks after the intervention.

Inclusion Criteria:

• Male or nonpregnant female
• Coronary patient hospitalised for elective PCI
• Hypercholesterolaemia defined as LDL-C ≥ 2 mmol/L

Exclusion Criteria:

• Any chronic inflammatory condition
• Chronic anti-inflammatory pharmacotherapy (except low-dose ASA)